barzolvolimab

all catalysts(0)

nothing on the calendar yet

News(7)

• Celldex sinks as safety concerns cloud immune drug results
  Though barzolvolimab displayed what one analyst described as the best efficacy results to date against chronic skin hives, treatment was also associated with two life-threatening anaphylaxis cases.
  biopharma_dive · 11d ago
• Celldex's hives drug faces safety questions despite Phase 3 successes
  Celldex said its experimental treatment barzolvolimab hit its primary endpoint in two Phase 3 trials, even as the readout raised safety concerns on two life-threatening cases of allergic reaction f…
  endpoints · 11d ago
• Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
  Celldex touted a double phase 3 trial win in patients with treatment-refractory chronic spontaneous urticaria.
  fiercebiotech · 12d ago
• STAT+: Pharma tries to tamp down broad China restrictions
  AI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The Readout
  stat · 2mo ago
• Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
  A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…
  biopharma_dive · 2mo ago
• Celldex ends skin disease program after failing phase 2 test
  A phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to end development in the indication and raising doubts about an upcoming e…
  fiercebiotech · 2mo ago
• 10 clinical trials to watch in the second half of 2026
  The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
  biopharma_dive · 3mo ago